Entrada Therapeutics(TRDA.US) Officer Sells US$26,282.1 in Common Stock
$Entrada Therapeutics(TRDA.US)$ Officer WENTWORTH KORY JAMES sold 1,758 shares of common stock on Jul 8, 2024 at an average price of $14.95 for a total value of $26,282.1.Source: Announcement What
Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Entrada Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 26.4% HC Wainwright & Co. $20 → $18 Maintains Buy 03/18/2024 40.45% HC Wainwright & Co. → $20 R
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $18
H.C. Wainwright analyst Ram Selvaraju maintains $Entrada Therapeutics(TRDA.US)$ with a buy rating, and adjusts the target price from $20 to $18.According to TipRanks data, the analyst has a success ra
Express News | Entrada Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $18 From $20
Express News | Entrada to Fund Clinical Trials With Offering Proceeds
Express News | Entrada Therapeutics Announces $100 Million Registered Direct Offering
Entrada Therapeutics Announced Preliminary Data From Its Phase 1 Trial For ENTR-601-44-101 In Healthy Volunteers, On Track To Submit Regulatory Applications In Q4 2024 To Initiate Separate Two Phase 2 Trials In Duchenne Muscular Dystrophy Patients
ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical
Express News | Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers From Phase 1 Entr-601-44-101 Trial for Duchenne Muscular Dystrophy
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Entrada Therapeutics, Inc. (NASDAQ:TRDA) is definitely a stock worth checking out, seeing as almost half of all the Biotechs companies
Entrada Therapeutics(TRDA.US) Officer Sells US$16,173.6 in Common Stock
$Entrada Therapeutics(TRDA.US)$ Officer Doshi Dipal sold 1,000 shares of common stock on Jun 13, 2024 at an average price of $16.1736 for a total value of $16,173.6.Source: Announcement What is statem
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new clas
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
Entrada Therapeutics(TRDA.US) Officer Sells US$287.69K in Common Stock
$Entrada Therapeutics(TRDA.US)$ Officer Sethuraman Natarajan sold 18,980 shares of common stock on May 16, 17, 20, 2024 at an average price of $15.1578 for a total value of $287.69K.Source: Announceme
Entrada Therapeutics(TRDA.US) Officer Sells US$45,129.12 in Common Stock
$Entrada Therapeutics(TRDA.US)$ Officer Doshi Dipal sold 3,000 shares of common stock on May 16, 17, 2024 at an average price of $15.043 for a total value of $45,129.12.Source: Announcement What is st
Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing
Natarajan Sethuraman, Chief Scientific Officer, on May 16, 2024, sold 18,980 shares in Entrada Therapeutics (TRDA) for $287,695. Following the Form 4 filing with the SEC, Sethuraman has control over a
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics(TRDA.US) Director Buys US$364.67K in Common Stock
$Entrada Therapeutics(TRDA.US)$ Director KIM PETER S purchased 25,000 shares of common stock on May 14, 2024 at an average price of $14.5869 for a total value of $364.67K.Source: Announcement What is
Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing
Peter S Kim, Director, on May 14, 2024, executed a purchase for 25,000 shares in Entrada Therapeutics (TRDA) for $364,673. Following the Form 4 filing with the SEC, Kim has control over a total of 92,